Skip to main content
    B

    Bio-Techne Corp (TECH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $72.79
    -0.01 (-0.01%)

    Market Cap: $11.44B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Bio-Techne Corp (TECH) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Bio-Techne (TECH) to earn $2.03 per share in the fiscal year ending Jun 30, 2027, on revenue of $1.28B. Of 13 analysts, 0 rate the stock Buy or Strong Buy, 12 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Jun 30, 2027 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 3.08, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 8% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy00.0%
    Hold1292.3%
    Sell17.7%
    Strong Sell00.0%
    Consensus
    Hold
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 13.8% and revenue estimates rise 9.4%.

    Fiscal year ending Jun 30, 2027
    $2.03
    EPS consensus, revenue $1.28B
    Fiscal year ending Jun 30, 2028
    $2.31
    EPS consensus, revenue $1.40B
    Next report
    Feb 2, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Jun 30, 2027$2.03$1.99 to $2.076$1.28B$1.28B to $1.29B4
    Jun 30, 2028$2.31$2.03 to $2.6010$1.40B$1.35B to $1.50B9

    Quarterly Estimates

    Across the 3 quarters below, the EPS consensus is lowest for the quarter ending Dec 31, 2026, at $0.48, and highest for the quarter ending Jun 30, 2027, at $0.58.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.48$0.46 to $0.517$308.14M$303.67M to $313.28M8
    Mar 31, 2027$0.56$0.55 to $0.597$328.49M$323.30M to $334.77M8
    Jun 30, 2027$0.58$0.53 to $0.6210$342.51M$321.54M to $361.63M12

    Estimate Revisions

    Across the 4 periods below, the last 30 days brought 4 upward and 2 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Jun 30, 202701
    Fiscal year ending Jun 30, 202830
    Quarter ending Dec 31, 202610
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Jun 30, 2027 has fallen 0.5% from $2.04.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Jun 30, 2027$2.03$2.04$2.02$2.02$2.04-0.7%
    Fiscal year ending Jun 30, 2028$2.31$2.31$2.31$2.31$2.30+0.4%
    Quarter ending Dec 31, 2026$0.48$0.48$0.48$0.47$0.480.0%
    Quarter ending Mar 31, 2027$0.56$0.56$0.56$0.55$0.56+0.5%

    Frequently Asked Questions About TECH

    What is the TECH stock forecast?

    Consensus analyst estimates put Bio-Techne's EPS at $2.03 for the fiscal year ending Jun 30, 2027, on revenue of $1.28B. The consensus rating from 13 analysts is Hold.

    How do analysts rate TECH stock?

    Of 13 analysts covering Bio-Techne, 0 rate it Strong Buy, 0 Buy, 12 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from TECH next year?

    For the fiscal year ending Jun 30, 2027, the consensus EPS estimate is $2.03, with estimates from $1.99 to $2.07 from 6 analysts. For the fiscal year ending Jun 30, 2028, the consensus EPS estimate is $2.31, with estimates from $2.03 to $2.60 from 10 analysts.

    What revenue do analysts expect from Bio-Techne next year?

    For the fiscal year ending Jun 30, 2027, the consensus revenue estimate is $1.28B, with estimates from $1.28B to $1.29B. For the fiscal year ending Jun 30, 2028, the consensus revenue estimate is $1.40B, with estimates from $1.35B to $1.50B.

    How many analysts cover TECH?

    13 analysts rate Bio-Techne stock, and 6 analysts estimate its EPS for the fiscal year ending Jun 30, 2027.